Targeting of Oncogenic Signaling Pathways by Berberine for Treatment of Colorectal Cancer Publisher Pubmed



Hallajzadeh J¹ ; Maleki Dana P² ; Mobini M³ ; Asemi Z² ; Mansournia MA⁴ ; Sharifi M⁵ ; Yousefi B⁶
Source: Medical Oncology Published:2020

Abstract

Studies indicate that inhibiting a single signaling pathway or one single product of a gene is insufficient for the prevention and treatment of cancer. This is due to the fact that dysregulation must occur in more than 500 genes in order to produce a cancerous phenotype. Despite this evidence, available drugs used for cancer treatment focus on a single target. Meanwhile, berberine as a nutraceutical is capable of targeting various processes involved in tumor development including proliferation, invasion, angiogenesis, and metastasis. In comparison with synthetic agents, berberine is cheaper, safer, and more available. Berberine has shown anti-inflammatory properties which make it an ideal option in order to prevent inflammation-associated cancers. Colorectal cancer is one of the most common cancers all over the world and its incidence is increasing each day. Therefore, further investigations about berberine could be helpful in the discovery of novel agents for preventing and/or treating colorectal cancer. This review emphasizes the studies investigating the roles of berberine in colorectal cancer such as controlling cell signaling pathways, inducing apoptosis, regulating microRNAs, attenuating oxidative stress, and affecting inflammation. © 2020, Springer Science+Business Media, LLC, part of Springer Nature.